NFX.LSE Nuformix plc

Healthcare Biotechnology London Exchange
0.0010 GBX
Close of Nov 3, 2026
0.0936 0.4000
Market cap
GBX 2.61M
P/E
-
P/B
1.71x
ROE
-84.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.

Is NFX.LSE undervalued?

Graham number

The Graham number of Nuformix plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Nuformix plc fundamental analysis

No fundamental analysis for Nuformix plc yet.

Nuformix plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Nuformix plc

Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for …

Full company profile